Following transient overexpression of constitutively-active SMAD3, a key mediator of TGF-β signaling, we noted significant rescue of GBM cytotoxicity from irinotecan and partial rescue of irinotecan + simvastatin cytotoxicity (Fig. 5g). Here, SMAD3 is linked to glioblastoma.